Protein / target
Solute carrier family 12 member 1
Protein at a glance
Biological role
Sodium:potassium:chloride symporter
Strongest disease association
Bartter Syndrome
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Renal sodium, potassium and chloride non-electrogenic ion symporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation.
View complete UniProt function annotationHide complete annotation
Renal sodium, potassium and chloride non-electrogenic ion symporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation (PubMed:21321328). It can substitute NH4(+) for K(+), enabling NH4(+) apical transmembrane transport in the medullary thick ascending limb (MTAL). This function is crucial for maintaining ammonium homeostasis by the kidney, particularly during metabolic acidosis (By similarity)
Subcellular location
Domains and Gene Ontology detail (16)Hide
Gene Ontology
- Capical plasma membrane
- Cextracellular exosome
- Cmembrane
- Cplasma membrane
- Fsodium:ammonium:chloride symporter activity
- Fsodium:potassium:chloride symporter activity
- Pammonium homeostasis
- Pcell volume homeostasis
- Pchloride ion homeostasis
- Pchloride transmembrane transport
- Pmonoatomic ion transmembrane transport
- Ppotassium ion homeostasis
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Ion channel gating
- ·monoatomic ion transmembrane transport
- ·sodium ion transmembrane transport
Chloride transport
- ·chloride ion homeostasis
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
5 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Sodium-(potassium)-chloride cotransporter 2 inhibitor
Indicated for Fibrosis, Heart Failure, Hypertension, Liver Cirrhosis
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene SLC12A1
Gene-level evidence surfaced through the gene SLC12A1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
5 compounds recorded · 5 approved
View all recorded compounds (5)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
View underlying tractability evidence (5)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
The Role of Furosemide Stress Test in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic
- Indication expanded
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
- Regulatory approval
Approval: Bopediat (EMA)
- Indication expanded
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
- Indication expanded
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
- Indication expanded
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
- Regulatory approval
Approval: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
- New publicationDiuretic strategies in patients with acute decompensated heart failure.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.